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Guidelines for the management of atherosclerotic cardiovascular
disease (ASCVD) recommend the use of risk stratification mod-
els to identify patients most likely to benefit from cholesterol-
lowering and other therapies. These models have differential per-
formance across race and gender groups with inconsistent behavior
across studies, potentially resulting in an inequitable distribution
of beneficial therapy. In this work, we leverage adversarial learning
and a large observational cohort extracted from electronic health
records (EHRs) to develop a "fair" ASCVD risk prediction model
with reduced variability in error rates across groups. We empirically
demonstrate that our approach is capable of aligning the distribu-
tion of risk predictions conditioned on the outcome across several
groups simultaneously for models built from high-dimensional EHR
data. We also discuss the relevance of these results in the context of
the empirical trade-off between fairness and model performance.
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1 INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD), which includes
heart attack, stroke, and fatal coronary heart disease, is a major
cause of mortality and morbidity worldwide, as well as in the U.S.,
where it contributes to 1 in 3 of all deaths–many of which are pre-
ventable [1]. In deciding whether to prescribe cholesterol-lowering
therapies to prevent ASCVD, physicians are often guided by risk
estimates yielded by the Pooled Cohort Equations (PCEs). PCEs pro-
vide a proportional hazards model [10] that leverages nine clinical
measurements to predict the 10-year risk of a first ASCVD event.
However this model has been found to overestimate risk for female
patients [25], Chinese patients [7] or globally [33], as well as also un-
derestimate risk for other groups such as Korean women [15]. Such
mis-estimation results in an inequitable distribution of the benefits
and harms of ASCVD risk scoring, because incorrect risk estimates
can expose patients to substantial harm through both under- or
over-treatment; potentially leading to preventable cardiovascular
events or side effects from unnecessary therapy, respectively.
The inability of the PCEs to generalize to diverse cohorts likely
owes to both under-representation of minority populations in the
cohorts used to develop the PCEs and shifts in medical practice
and lifestyle patterns in the decades since data collection for those
cohorts. In attempting to correct for these patterns, one recent
study [33] updated the PCEs using data from contemporary cohorts
and demonstrated that doing so reduced the number of minority
patients incorrectly misclassified as being high or low risk. Similar
results were observed in the same study with an approach using
an elastic net classifier, rather than a proportional hazards model.
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However, neither approach is able to explicitly guarantee an eq-
uitable distribution of mis-estimation across relevant subgroups,
particularly for race- and gender-based subgroups.
To account for under-represented minorities and to take advan-
tage of the wider variety of variables made available in electronic
health records (EHRs), we derive a large and diverse modern cohort
from EHRs to learn a prediction model for ASCVD risk. Further-
more, we investigate the extent to which we can encode algorithmic
notions of fairness, specifically equality of odds, [13] into the model
to encourage an equitable distribution of performance across pop-
ulations. To the best of our knowledge, our effort is the first to
explore the extent to which this formal fairness metric is achievable
for risk prediction models built using high-dimensional data from
the EHR. We show that while it is feasible to develop models that
achieve equality of odds, we emphasize that this process involves
trade-offs that must be assessed in a broader social and medical
context [32].
2 BACKGROUND AND RELATEDWORK
2.1 ASCVD Risk Prediction and EHRs
The PCEs are based on age, gender, cholesterol levels, blood pres-
sure, and smoking and diabetes status and were developed by pool-
ing data from five large U.S. cohorts [10] composed of white and
black patients, with white patients constituting a majority. Recently,
attempts [33] were made to update the PCEs to improve model per-
formance for race- and gender-based subgroups using elastic net
regression and data from modern prospective cohorts. However,
this effort focused on demographic groups and variables already
used to develop the PCEs and did not consider other populations
or clinical measurements. The increasing adoption of EHRs offers
opportunities to deploy and refine ASCVD risk models. Efforts have
recently been undertaken to apply and refine existing models, in-
cluding the PCEs and the Framingham score, to large EHR-derived
cohorts and characterize their performance in certain subgroups
[28, 30]. Beyond ASCVD risk prediction, there exist many recent
works that develop prediction models with EHRs, which are re-
viewed in [11].
2.2 Fair Risk Prediction
We consider the case where supervised learning is used to estimate
a function f (X ) that approximates the conditional distribution
p(Y |X ), given N samples {xi ,yi , zi }Ni=1 drawn from the distribu-
tion p(X ,Y ,Z ). We take X ∈ X = Rm to correspond to a vector
representation of the medical history extracted from the EHR prior
to a patient-specific index time ti ; Y ∈ Y = {0, 1} to be a binary
label, which for patient i , indicates the presence of the outcome
observed in the EHR in the time frame [ti , ti +wi ], wherewi is a
parameter specifying the amount of time following the index time
used to derive the outcome; and Z ∈ Z = {0, . . . ,k − 1} indicates a
sensitive attribute, such as race, gender, or age, with k groups. The
output of the learned function f (X ) ∈ [0, 1] is then thresholded
with respect to a value T to yield a prediction Ŷ ∈ {0, 1}.
One standard metric for assessing the fairness of a classifier
with respect to a sensitive attribute Z is demographic parity [8],
which evaluates the independence between Z and the prediction Ŷ .
Formally, the demographic parity criterion may be expressed as
p(Ŷ |Z = Zi ) = p(Ŷ |Z = Z j )∀Zi ,Z j ∈ Z. (1)
However, optimizing for demographic parity is of limited use for
clinical risk prediction, because doing so may preclude the model
from considering relevant clinical features associated with the sen-
sitive attribute and the outcome, thus decreasing the performance
of the model for all groups [20].
Another related metric is equality of odds [13], which stipulates
that the prediction Ŷ be conditionally independent of Z , given the
true label Y . Formally, satisfying equality of odds implies that
p(Ŷ |Z = Zi ,Y = Yk ) = p(Ŷ |Z = Z j ,Y = Yk )
∀Zi ,Z j ∈ Z;Yk ∈ Y. (2)
From this, it can be seen that, if equality of odds is achieved, then
for a fixed threshold T , both the false positive (FPR) and false nega-
tive rates (FNR) are equal across all pairs of groups defined by Z .
Compared to demographic parity, equality of odds is more appro-
priate in a clinical setting, since it does not necessarily preclude the
learning of the optimal predictor in the case that a true relationship
between sensitive attribute and the outcome exists [13].
Furthermore, this definition can be extended to the case of a
continuous risk score by requiring that
p(f (X )|Z = Zi ,Y = Yk ) = p(f (X )|Z = Z j ,Y = Yk )
∀Zi ,Z j ∈ Z;Yk ∈ Y. (3)
In this case, the distribution of the predicted probability of the
outcome conditioned on whether the event occurred or not should
be matched across groups of a sensitive variable. Formulation 3 is
stronger than 2 since it implies that equality of odds is achieved
for all possible thresholds, thus requiring that the same ROC curve
be attained for all groups. This is desirable since it provides the
end-user the ability to freely adjust the decision threshold of the
model without violating equality of odds.
Finally, we also note that satisfying equality of odds for a con-
tinuous risk score may be reduced to the problem of minimizing
a divergence over each pair (Zi ,Z j ) of distributions referenced in
equation (3). Adversarial learning procedures [12] are well-suited
to this problem in that they provide a flexible framework for mini-
mizing the divergence over distributions parameterized by neural
networks. As such, several related works [2, 9, 24, 34] have demon-
strated the benefit of augmenting a classifier with an adversarial
discriminator in order to align the distribution of predictions for
satisfying fairness constraints.
2.3 Approaches for Achieving Fairness
Despite considerable interest in the ethical implications of imple-
menting machine learning in healthcare [4, 6], relatively little work
exists characterizing the extent to which risk prediction models
developed with EHR data satisfy formal fairness constraints.
Adversarial approaches for satisfying fairness constraints (in the
form of demographic parity) have been explored in several recent
works in non-healthcare domains. One approach, [9], in the con-
text of image anonymization, demonstrated that representations
satisfying demographic parity could be learned by augmenting
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a predictive model with both an autoencoder and an adversarial
component. The adversarial approach to fairness was further in-
vestigated by [2] with a gradient reversal objective for data that
is imbalanced in the distribution of both the outcome and in the
sensitive attribute.
In attempting to address the limitations of demographic parity
as a metric, [13] introduced equality of odds as an alternative and
devised post-processing methods to achieve it for fixed-threshold
classifiers. Recently, [34] and [24] generalized the adversarial frame-
work to achieve equality of odds by providing the discriminator
access to the value of the outcome.
Both demographic parity and equality of odds are referred to
as group fairness metrics since they are concerned with encourag-
ing an invariance of some property of a classifier over groups of
a sensitive attribute. While straightforward to compute and rea-
son about, optimizing for these metrics may produce models that
are discriminatory over structured subgroups within and across
groups of sensitive attributes, constituting a form of fairness ger-
rymandering [17]. The competing notion of individual fairness [8]
and may be able to address these concerns by assessing whether a
model produces similar outputs for similar individuals. However,
this notion is often of limited practical use due to the challenges of
developing a domain-specific similarity metric that encodes desired
notions of fairness.
Recent efforts [14] have investigated an alternative to both group
and individual fairness metrics with a process that audits a classifier
to discover subgroups for which the model is under-performing and
iteratively improve model performance for those groups, ultimately
resulting in a non-negative change in model performance for all
computationally-identifiable subgroups.
The closest related work examining the fairness of risk predic-
tion models in healthcare is [5], which, in the context of mortality
prediction in intensive care units, argued that any trade-off between
model performance and fairness across subgroups is undesirable.
They propose that the prediction error should be decomposed in
terms of bias, variance, and noise and that the relative contribution
of these terms be used to guide additional data collection.
3 METHODS
3.1 The Dataset and Cohort Definition
We extract records from the Stanford Medicine Research Data
Repository [23], a clinical data warehouse containing records on
roughly three million patients from Stanford Hospital and Clinics
and Lucile Packard Children’s Hospital for clinical encounters oc-
curring between 1990 and 2017. We define a prediction task that
resembles the setting in which the PCEs were developed for the pur-
pose of guiding physician decision-making in ASCVD prevention
and construct a corresponding cohort. As a first step, we identify
all patients with at least two clinical encounters over at least two
years for which they are 40 years of age or older. Then, for each
patient we select an index time ti uniformly at random from the
interval that allows for at least one year of history and one year of
follow-up. We exclude from the cohort patients that have an his-
tory of cardiovascular artery disease (including ASCVD and atrial
fibrillation) or a prescription of an anti-hypertensive drug in the
five years prior to the index time.
Table 1: Cohort characteristics. The number of patients ex-
tracted, the incidence of the ASCVD outcome and the aver-
age length of follow-up for each subgroup are shown.
Group Count ASCVDIncidence (%)
Follow-up
Length (years)
Asian 30,294 2.3 3.2
Black 8,549 3.0 3.2
Hispanic 20,240 2.0 2.9
Other 19,062 2.2 3.1
Unknown 39,964 0.86 3.1
White 135,438 2.8 3.6
Female 149,594 1.9 3.4
Male 103,953 2.9 3.3
40-55 121,437 0.95 3.4
55-65 61,214 2.1 3.5
65-75 43,800 3.7 3.2
75+ 27,096 6.7 3.0
All 253,547 2.8 3.4
Finally, we assign a positive ASCVD label for a patient if a diag-
nosis code for an ASCVD event is observed at any point in their
record following the index time. The exclusion criteria (i.e. the list
of cardiovascular-related diseases and medications) is provided as
supplementary material, along with the list of clinical concepts
used for defining ASCVD events. The patients are randomly par-
titioned such that 80%, 10%, 10% are used for training, validation,
and testing, respectively.
3.2 Sensitive Attributes
We consider race, gender, and age as sensitive attributes and assess
model performance and fairness with respect to them. For race,
we use both race and ethnicity variables to partition the cohort
into six disjoint groups: Asian, Black, Hispanic, Other, Unknown,
and White. Patients not considered Hispanic thus have either a
non-Hispanic or unknown ethnicity. For gender, we partition the
cohort into male and female populations. For age, we discretize the
age at the index time into four disjoint groups: 40-55, 55-65, 65-75,
and 75+ years, where the intervals are inclusive on the lower bound
and exclusive on the upper bound. A summary of these groups is
presented in Table 1.
3.3 Feature Extraction
For feature extraction, we adopt a strategy similar to the one de-
scribed in [31] to convert time-stamped sequences of clinical con-
cepts across several domains (i.e., diagnoses, procedures, medication
orders, lab tests, clinical encounter types, departments, and other
observations) into a static representation suitable for modeling. For
each extracted patient, we filter the historical record to include
only those concepts occurring prior to the index time. We encode
as a binary attribute each unique clinical concept observed in the
dataset according to whether that concept was present anywhere
in the patient’s history prior to the prediction time; otherwise, it is
absent or missing. Similarly, we do not use the numeric results of
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Table 2: Distribution alignment metrics. We report the coefficient of variation (CV; the ratio of the standard deviation to the
mean) of the false positive rate (FPR, CV) and false negative rate (FNR, CV) at a fixed decision threshold of 0.075 across the
race, gender, and age groups. Furthermore, we compute the pairwise earth mover’s distance (EMD) between distributions of
the predicted probabilities of having an ASCVD event, conditioned on the true ASCVD label y for each group of each sensitive
attribute and take the mean.
Race Gender Age
Standard EQrace Standard EQgender Standard EQage
FNR, CV 0.126 0.1 0.102 0.0164 0.382 0.129
FPR, CV 0.538 0.383 0.45 0.12 1.05 0.205
Mean EMD | y = 0 0.00749 0.00616 0.00875 0.0026 0.0239 0.00312
Mean EMD | y = 1 0.0226 0.0237 0.0167 0.00593 0.0602 0.0209
lab tests or vital measurements, but only include the presence of
their measurement. In all models, we include race, gender, and age
as features without regards as to whether the variable is treated as
sensitive or not.
3.4 Adversarial Learning for Equality of Odds
To develop an ASCVD risk prediction model that satisfies the defi-
nition of equality of odds in (3), we consider two fully-connected
neural networks: a classifier f : Rm → R ∈ [0, 1] parameterized
by θf that predicts the probability of the ASCVD outcome Y given
data X ; and a discriminator д : R × {0, 1} → [0, 1]k parameterized
by θд that takes as input both the logit of the output of f and the
value of the true label Y to predict a distribution over the groups
of a sensitive attribute Z . If Lcls and Ladv are the cross-entropy
losses of the classifier predictions over Y and the discriminator
predictions over Z , respectively, then the training procedure may
be described by alternating between the steps
min
θf
Lcls − Ladv and min
θд
Ladv . (4)
3.5 Model Training and Evaluation
The training procedure is composed of four experiments and thus
produces four prediction models. The first model is trained to pre-
dict the risk of ASCVD and does not use adversarial training. The
other three models result from separate training runs in which
each of the discrete race, gender, and age variables are considered
as sensitive attributes in the adversarial training procedure. We
refer to these four experiments as Standard, EQrace, EQgender, and
EQage.
For all experiments, we employ fully-connected feedforward
neural networks with a fixed set of hyperparameters. The ASCVD
prediction model is composed of the sum over an embedding layer
of dimension 100 followed by two hidden layers of dimension 128
and leaky ReLU nonlinearities. The adversarial network maintains a
similar architecture, but with one hidden layer of dimension 64 and
takes the prediction logit and ASCVD outcome as inputs. Training
proceeds in a batch setting with the Adam optimizer [19] with
learning rate 10−3, β1 = 0.5, and β2 = 0.9 with batch size 256
over the training set and early stopping based on the area under
the receiver operating characteristic curve (AUC-ROC) for ASCVD
Table 3: Model performance measured on the test set with-
out stratification for each experimental condition.
Standard EQrace EQgender EQage
AUC-ROC 0.793 0.772 0.779 0.743
AUC-PRC 0.133 0.125 0.13 0.0965
Brier Score 0.0205 0.0207 0.0206 0.0211
prediction in the validation set. All training was performed on a
single GPU with the PyTorch library [27].
For each model, we compute standard metrics on the entire test
set and on each subgroup. Specifically, we report the AUC-ROC, the
area under the precision-recall curve (AUC-PRC), the Brier score [3]
as a measure of calibration, and the false positive and false negative
rates (FPR, FNR) at a fixed threshold of T = 0.075, in keeping with
current ASCVD guidelines for the prescription of statin therapy
[10, 33]. To express adherence to the standard equality of odds
definition in equation 2, we report the coefficient of variation (i.e.
the ratio of the standard deviation to the mean) of the FPR and FNR
atT = 0.075 across the groups of each sensitive attribute. To assess
the distance between the distributions presented in (3), we compute
the earth mover’s distance (EMD, or first Wasserstein distance)
between the empirical distributions of the predicted probability of
ASCVD conditioned on whether ASCVD occurred or not for each
group of each sensitive attribute in a pairwise fashion and take the
mean within each strata.
4 RESULTS
4.1 Cohort Characteristics
The cohort extraction procedure produces a cohort of 253,547 pa-
tients having 71,554 features, with 5,886 patients labeled as positive
for ASCVD (Table 1). We note that in this cohort, there are 135,438
white patients, constituting a majority, and 8,549 black patients.
Across racial groups, ASCVD rates range from 2.0-3.0%, with the
exception of patients with unknown race, who experience a reduced
rate of 0.86%. Furthermore, we observe higher ASCVD rates for
male patients compared to female patients. Finally, ASCVD rates
appear to increase monotonically with age, with rates ranging from
0.95% for the 40-55 age group to 6.7% for patients age 75 or older.
Spotlight 2: Fairness and Explanations AIES’19, January 27–28, 2019, Honolulu, HI, USA
274
Table 4: Model performance measured on the test set stratified by group and experimental condition. EQ corresponds to train-
ing for the sensitive attribute corresponding to the subgroup of interest. FPR and FNR are computed at a fixed decision thresh-
old of 0.075.
AUC-ROC AUC-PRC Brier Score FNR FPR
Stand. EQ Stand. EQ Stand. EQ Stand. EQ Stand. EQ
Asian 0.819 0.771 0.138 0.155 0.0196 0.0197 0.683 0.587 0.0388 0.0903
Black 0.753 0.756 0.162 0.2 0.034 0.0338 0.621 0.69 0.0781 0.0437
Hispanic 0.811 0.803 0.117 0.0816 0.0142 0.015 0.667 0.6 0.0391 0.0945
Other 0.813 0.822 0.13 0.113 0.0217 0.0219 0.711 0.556 0.0544 0.102
Unknown 0.713 0.718 0.0619 0.0406 0.00766 0.00812 0.844 0.719 0.00944 0.0353
White 0.774 0.766 0.146 0.155 0.0245 0.0245 0.6 0.619 0.0804 0.0714
Female 0.8 0.786 0.12 0.122 0.0173 0.0174 0.684 0.625 0.0423 0.0567
Male 0.775 0.769 0.148 0.143 0.0249 0.025 0.592 0.64 0.0818 0.0672
40-55 0.713 0.727 0.0404 0.0275 0.0085 0.00922 0.952 0.817 0.00683 0.0573
55-65 0.736 0.708 0.0919 0.0676 0.0195 0.0198 0.794 0.746 0.0409 0.0618
65-75 0.736 0.739 0.128 0.141 0.0349 0.0347 0.608 0.669 0.115 0.088
75+ 0.776 0.763 0.228 0.224 0.053 0.0548 0.351 0.607 0.251 0.0806
Figure 1: Empirical distribution of the predicted probability
of developingASCVD in the followup period conditioned on
whether ASCVD occurred. Plots are stratified by experimen-
tal condition (Standard or EQ), true value of the ASCVD out-
come (y = 0 or y = 1), and the variable treated as sensitive
(race, gender, or age).
4.2 Distribution Alignment with Adversarial
Training
Applying the adversarial training procedure results in a alignment
of the distributions of the predicted probability of ASCVD condi-
tioned on the true outcome label (Figure 1). Without employing a
adversarial discriminator, the center of mass of these distributions
appears to depend significantly on the base ASCVD rate in the
group. However, these differences largely disappear when training
in an adversarial setting. This results in a substantial reduction
in the mean pairwise EMD between each predictive distribution
in both outcome strata for both gender and age, with a negligible
effect for race (Table 2). Furthermore, we note that variability in the
FPRs and FNRs at a fixed threshold of 0.075 is greatly reduced fol-
lowing adversarial training (Table 2), indicating that the approach
successfully encourages the model predictions to satisfy equality
of odds.
The relative lack of success in minimizing the mean pairwise
EMD between the conditional predictive distributions across racial
groups (Table 2) may be largely explained by the anomalous charac-
teristics of the group of patients having unknown race. For instance,
when using standard training (Standard), the predictive distribu-
tion conditioned on a positive ASCVD outcome for the unknown
race group is clearly separated from that of the five groups while
the distributions for those five are mostly aligned (Figure 1). How-
ever, when training the model in an adversarial setting, it appears
that the primary effect is to align the predictive distribution for the
unknown race group to the region inhabited by the distributions
of the remaining groups while disturbing the relative alignment
between the distributions for those groups.
4.3 The Cost of Fairness
Satisfying equality of odds with an adversarial objective incurs a re-
duction in AUC-ROC, AUC-PRC, and calibration for the population
at large (Table 3), with the largest negative effects observed when
training to adjust for the differences across age groups (Standard
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AUC-ROC = 0.793 vs. EQage AUC-ROC = 0.743). However, for rank-
ing metrics such as the AUC-ROC, the effects can be unintuitive
following an adjustment of the subgroup predictive distributions.
For instance, the adversarial training procedure for age actually
leads to an increase in AUC-ROC for the majority 40-55 years group
(Standard AUC-ROC = 0.713 vs. EQage AUC-ROC = 0.727) (Table
4) despite the stark decline in the AUC-ROC observed on the popu-
lation as a whole. Furthermore, several of the populations assessed
experience a reduction in performance for some metrics with im-
provements in others following training for equality of odds. In
other cases, the effect is largely positive. Notably, model perfor-
mance improves on all metrics except for the fixed threshold FNR
for the black population, a group for which the model attains the
lowest AUC-ROC (0.753) and is the least well-calibrated (Brier Score
= 0.034) for the standard setting.
It has been shown that developing a well-calibrated model is
an objective that conflicts with that of satisfying equality of odds
[20, 29]. In our case, we observed such a trade-off, but judged it to
be minor due to a small increase in the Brier score for almost every
subgroup following training for equality of odds (Table 2).
5 DISCUSSION
We have demonstrated the capabilities of adversarial training proce-
dures to encourage the learning of models whose predictions satisfy
equality of odds for high-dimensional EHR data with sensitive at-
tributes of more than two groups. In a setting such as ASCVD risk
prediction, with a clear clinical intervention associated with the
prediction, this procedure ensures that no group bears a disparate
burden of mistreatment due to misclassification. However, we note
that this comes at a cost of a reduction in AUC-ROC and AUC-PRC
for some subgroups.
5.1 Limitations of the Predictive Model
While using EHR data allowed a high-capacity ASCVD risk predic-
tion model to be trained using a large and diverse cohort, this model
should not be directly compared to the PCEs for several reasons.
First, the PCEs estimate ten-year ASCVD risk, whereas our model
estimates risk over a period of at least a year. Furthermore, we
cannot rule out the existence of biases that may lead to differential
rates of selection or censoring in our cohort across age, gender,
and race based subgroups, nor can we establish whether the nature
of these biases differ from those present in the prospective cohort
studies used to derive the PCEs.
5.2 Moving Beyond Equality of Odds
While we have demonstrated empirically that adversarial learning
procedures are capable of encouraging a model to satisfy equality
of odds, the use of this metric as a measure of fairness should
be approached with caution. In the case that there is insufficient
information in the training dataset to learn a high performingmodel
for at least one group, optimizing for this criteria will upper bound
the group-level model performance by the performance obtained for
the least-well performing group. In the adversarial learning setting,
this reduction in performance for some groups may be offset by
performance gains for groups for which the model performs poorly
when trained naively. However, we observed that if such a benefit
exists, it is smaller than the reduction in performance incurred for
most groups.
We have not examined the relationship between the errors of
the predictive model and notions of long-term utility when deploy-
ing the model clinically. To properly analyze the effect of these
errors on utility requires careful causal modeling of the sequential
decision-making process following ASCVD risk prediction while
accounting for individual patient characteristics. We emphasize
that while such a process is crucial to evaluate the long-term im-
pact of any prediction model, it is not possible to properly identify
and model that causal process with observational data in the EHR
alone [18]. Additionally, it is unclear that satisfying fairness con-
straints for a single-step decision, as in ASCVD risk prediction,
aligns with the goal of equitably maximizing long-term utility, as
it has been shown that satisfying fairness constraints for a static
decision may actually cause long-term harm in settings where an
unconstrained objective would not [22], particularly if the outcome
is measured with bias due to systematic censoring [16]. We find
those approaches [21, 26] that establish causal notions of fairness to
be promising directions for future work, as they permit sequential
decision making processes to be studied under the lens of fairness
at both the group and individual level.
6 CONCLUSION
Existing approaches to ASCVD risk scoring perform poorly for
the population at large, with more extreme risk mis-estimates for
minority populations, inadvertently exposing those groups to ex-
cess harm. We develop an ASCVD prediction model using EHR
data and show that we can encourage formal notions of fairness by
reducing the variability in the FPR and FNR across groups. It is not
yet known to what extent algorithmic notions of fairness align with
other goals, including long-term utility maximization. We hope that
our results will serve as an impetus for the community at large to
investigate the fairness-utility trade-off during sequential clinical
decision making resulting from fairness constraints imposed on
clinical risk assessments.
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A EXCLUSION CRITERIA:
CARDIOVASCULAR ARTERY DISEASES
Here we list the set of concepts from the Observational Medical
Outcomes Partnership vocabulary version 5.3 used to exclude pa-
tients on the basis of a history of cardiovascular artery disease at
the prediction time.
Monoplegia of dominant lower limb as a late effect of cerebrovas-
cular accident (197303); Acute myocardial infarction (312327); Hy-
pertensive encephalopathy (312938); Atrial fibrillation (313217);
Nonpyogenic thrombosis of intracranial venous sinus (314667);
Chronic ischemic heart disease (315286); Preinfarction syndrome
(315296); Angina decubitus (315832); Heart failure (316139); Aneurysm
of coronary vessels (316427); Cerebral atherosclerosis (316437);
Coronary occlusion (316995); Coronary arteriosclerosis (317576);
Postmyocardial infarction syndrome (319038); Congestive heart
failure (319835); Angina pectoris (321318); Dissecting aneurysm of
coronary artery (321879); Paralytic syndrome as late effect of stroke
(372654); Cerebral artery occlusion (372924); Transient cerebral is-
chemia (373503); Basilar artery syndrome (374055); Acute ill-defined
cerebrovascular disease (374060); Cerebral ischemia (374384); Cere-
bral embolism (375557); Vertebrobasilar artery syndrome (376714);
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Moyamoya disease (378774); Cerebrovascular disease (381591); Sub-
clavian steal syndrome (433505); Late effects of cerebrovascular dis-
ease (434056); Acute myocardial infarction of anterior wall (434376);
Vertebral artery syndrome (434656); Weakness of face muscles
(434657); Acute myocardial infarction of lateral wall (436706); Basi-
lar artery occlusion (437308); Ataxia (437584); Aneurysm of heart
(438168); Acute myocardial infarction of inferior wall (438170);
Acute myocardial infarction of anterolateral wall (438438); Acute
myocardial infarction of inferolateral wall (438447); Multiple and
bilateral precerebral arterial occlusion (439295); True posterior my-
ocardial infarction (439693); Left heart failure (439846); Vertigo
as late effect of stroke (440426); Acute myocardial infarction of
inferoposterior wall (441579); Cerebral thrombosis (441874); Pre-
cerebral arterial occlusion (443239); Dysphagia as a late effect of
cerebrovascular accident (443465); Monoplegia of dominant upper
limb as a late effect ofcerebrovascular accident (443525); Apraxia
due to cerebrovascular accident (443551); Arteriosclerosis of coro-
nary artery bypass graft (443563); Systolic heart failure (443580);
Diastolic heart failure (443587); Paralytic syndrome of nondomi-
nant side as late effect of stroke (443599); Paralytic syndrome of
dominant side as late effect of stroke (443609); Acute subendocar-
dial infarction (444406); Infarction - precerebral (4043731); Verte-
brobasilar territory transient ischemic attack (4048785); Cerebral
infarction due to embolism of cerebral arteries (4108356); Acute
myocardial infarction of atrium (4108669); Cerebral infarction due
to thrombosis of cerebral arteries (4110192); Occlusion of artery
(4162038); Vertebral artery obstruction (4185117); Ischemic heart
disease (4185932); Myocardial ischemia (4186397); Carotid artery ob-
struction (4288310); Chronic systolic heart failure (40479192); Dys-
phasia as late effect of cerebrovascular disease (40479575); Chronic
diastolic heart failure (40479576); Aphasia as late effect of cere-
brovascular disease (40480002); Sensory disorder as a late effect
of cerebrovascular disease (40480449); Acute on chronic systolic
heart failure (40480602); Acute systolic heart failure (40480603);
Monoplegia of lower limb as late effect of cerebrovascular disease
(40480938); Monoplegia of nondominant lower limb as a late effect
of cerebrovascular accident (40480946); Acute diastolic heart failure
(40481042); Acute on chronic diastolic heart failure (40481043); Ar-
teriosclerosis of coronary artery bypass graft of transplanted heart
(40481132); Speech and language deficit as late effect of cerebrovas-
cular accident (40481354); Hemiplegia as late effect of cerebrovas-
cular disease (40481762); Monoplegia of upper limb as late effect
of cerebrovascular disease (40481842); Coronary atherosclerosis
(40481919); Monoplegia of nondominant upper limb as a late effect
of cerebrovascular accident (40482266); Residual cognitive deficit
as late effect of cerebrovascular accident (40482301); Arterioscle-
rosis of autologous vein coronary artery bypass graft (40482638);
Arteriosclerosis of nonautologous coronary artery bypass graft
(40482655); Combined systolic and diastolic dysfunction (40482727);
Arteriosclerosis of arterial coronary artery bypass graft (40483189);
Hemiplegia of nondominant side as late effect of cerebrovascular
disease (40484513); Hemiplegia of dominant side as late effect of
cerebrovascular disease (40484522); Coronary arteriosclerosis in
native artery (42872402); Coronary arteriosclerosis in native artery
of transplanted heart (43021821); Dysarthria as late effects of cere-
brovascular disease (43530687); Visual disturbance as sequela of
cerebrovascular disease (43531583); Acute combined systolic and
diastolic heart failure (44782718); Chronic combined systolic and di-
astolic heart failure (44782719); Acute on chronic combined systolic
and diastolic heart failure (44782733).
B EXCLUSION CRITERIA:
ANTIHYPERTENSIVE DRUGS
Here we list the medications from the Antomatical Therapeutic
Chemical Classification System (ATC) used to exclude patients on
the basis of a history of prescription of anti-hypertensive drugs at
the prediction time.
Rauwolfia alkaloids (C02AA); rescinnamine (C02AA01); reser-
pine (C02AA02); deserpidine (C02AA05); methoserpidine (C02AA06);
methyldopa (levorotatory) (C02AB01); clonidine (C02AC01); guan-
facine (C02AC02); moxonidine (C02AC05); rilmenidine (C02AC06);
trimetaphan (C02BA01); mecamylamine (C02BB01); prazosin (C02CA01);
indoramin (C02CA02); doxazosin (C02CA04); urapidil (C02CA06);
betanidine (C02CC01); guanethidine (C02CC02); debrisoquine (C02CC04);
diazoxide (C02DA01); dihydralazine (C02DB01); hydralazine (C02DB02);
minoxidil (C02DC01); nitroprusside (C02DD01); pinacidil (C02DG01);
metirosine (C02KB01); pargyline (C02KC01); ketanserin (C02KD01);
bosentan (C02KX01); ambrisentan (C02KX02); macitentan (C02KX04);
riociguat (C02KX05); alprenolol (C07AA01); oxprenolol (C07AA02);
pindolol (C07AA03); propranolol (C07AA05); timolol (C07AA06);
sotalol (C07AA07); nadolol (C07AA12); mepindolol (C07AA14);
carteolol (C07AA15); tertatolol (C07AA16); bopindolol (C07AA17);
bupranolol (C07AA19); penbutolol (C07AA23); practolol (C07AB01);
metoprolol (C07AB02); atenolol (C07AB03); acebutolol (C07AB04);
betaxolol (C07AB05); bisoprolol (C07AB07); celiprolol (C07AB08);
esmolol (C07AB09); nebivolol (C07AB12); talinolol (C07AB13); la-
betalol (C07AG01); carvedilol (C07AG02); metoprolol and felodipine
(C07FB02); atenolol and nifedipine (C07FB03).
C OUTCOME DEFINITION: ASCVD
Here we list the set of concepts from the Observational Medical
Outcomes Partnership vocabulary version 5.3 used to define the
presence of ASCVD in the followup period.
Acute myocardial infarction (312327); Cerebral artery occlusion
(372924); Acute ill-defined cerebrovascular disease (374060); Cere-
bral embolism (375557); Acutemyocardial infarction of anterior wall
(434376); Acute myocardial infarction of lateral wall (436706); Basi-
lar artery occlusion (437308); Acute myocardial infarction of infe-
rior wall (438170); Acute myocardial infarction of anterolateral wall
(438438); Acute myocardial infarction of inferolateral wall (438447);
Multiple and bilateral precerebral arterial occlusion (439295); True
posterior myocardial infarction (439693); Acute myocardial infarc-
tion of inferoposterior wall (441579); Cerebral thrombosis (441874);
Precerebral arterial occlusion (443239); Acute subendocardial infarc-
tion (444406); Infarction - precerebral (4043731); Cerebral infarction
due to embolism of cerebral arteries (4108356); Acute myocardial
infarction of atrium (4108669); Cerebral infarction due to throm-
bosis of cerebral arteries (4110192); Vertebral artery obstruction
(4185117); Carotid artery obstruction (4288310).
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